Literature DB >> 16259865

Minimally invasive surgery in prostate cancer: current and future perspectives.

Bulent Akduman1, Al Baha Barqawi, E David Crawford.   

Abstract

Prostate cancer is a leading cause of death for men. Its prevalence increases substantially with advancing age, which coincides with increased incidence of comorbidities. The mainstay therapy for early prostate cancer remains radical surgery and radiotherapy. In the era of prostate-specific antigen and the newly emerging highly specific screening tests, more men are diagnosed earlier in their life and with confined disease. The application of minimally invasive approaches, such as the laparoscopic/telerobotic approach and focal treatments, is becoming more popular, yielding shorter hospital stays and faster recovery, with minimal complications. In part, this is possible due to groundbreaking advances in laparoscopic equipment, prostate imaging modalities, and gained urologic expertise in minimally invasive treatment. In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16259865     DOI: 10.1097/00130404-200509000-00001

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  2 in total

1.  Efficacy of solifenacin in the prevention of short-term complications after laparoscopic radical prostatectomy.

Authors:  Ranxing Yang; Lijie Liu; Gaofeng Li; Jianjun Yu
Journal:  J Int Med Res       Date:  2017-06-29       Impact factor: 1.671

Review 2.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.